Work

Reduced half-life of recombinant ADAMTS13 in a patient with cTTP undergoing total hip arthroplasty

Year: 2025

Type: article

Abstract: A 41 year old female with congenital thrombotic thrombocytopenic purpura (cTTP) underwent a total hip arthroplasty under prophylaxis with recombinant ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13). The procedure was performed without complications 12 h after the last injection. Postoperative ADAMTS13 activity levels showed a more rapid decrease in activity and in the individual apparent half-life due to increased consumption of the recombinant protease that could safely be managed by an intensified dosing regimen.

Source: Thrombosis Journal

DOI: 10.1186/s12959-025-00792-y

Authors: Maria Weise, Thomas Siegemund, Tristan Klöter, Maren Keller, Sirak Petros, Christian Pfrepper

Institutions: University Hospital Leipzig, Leipzig University

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,090